Moderna, Pharma Stocks Fall as FDA Names Industry Critic as Top Vaccine Regulator
Trump wants to impose tariffs on Pharmaceuticals: Pharmaceutical companies are busy stockpiling, and the import volume in the USA surged in March.
① The volume of Pharmaceutical imports in the USA surged in March, as pharmaceutical companies stockpiled products in anticipation of potential tariffs; ② A report released by the US Department of Commerce on Tuesday showed that the total value of Pharmaceutical imports in March exceeded 50 billion USD, equivalent to 20% of the total Pharmaceutical imports for the entire year of 2024.
Argus Research Maintains Pfizer(PFE.US) With Hold Rating
Trump Sets Pharma Tariffs Deadline. The Fallout for Lilly, Pfizer, Other Drugmakers
Pfizer Options Spot-On: On May 6th, 196.49K Contracts Were Traded, With 3.44 Million Open Interest
Market Chatter: Expanded Indication for GSK, Pfizer RSV Vaccines Faces Government Review
Trump Administration Cancels Meeting With FDA Workers Union - Report
Express News | Shares of Vaccine and Gene Therapy Stocks Are Trading Lower After FDA Commissioner Marty Makary Reportedly Named Vinay Prasad as Director of the Center for Biologics and Research
Express News | 'FDA Names Vinay Prasad as New Head of Vaccines, Biologics'- Bloomberg Law
Express News | Moderna Falls 12%, Pfizer Falls 3.3% and Novavax Falls 6.3%
FDA Plans to Increase Surprise Inspections at Overseas Manufacturing Sites
10 Health Care Stocks With Whale Alerts In Today's Session
Trump Sets Pharma Tariffs Deadline. The Fallout for Lilly, Pfizer, Other Drugmakers. -- Barrons.com
Analysts Offer Insights on Healthcare Companies: Pfizer (PFE), Personalis (PSNL) and Omnicell (OMCL)
Do These 3 Checks Before Buying Pfizer Inc. (NYSE:PFE) For Its Upcoming Dividend
'Trump To Sign Order To Encourage Domestic Drug Manufacturing' - Washington Post
Pfizer Options Spot-On: On May 5th, 104.31K Contracts Were Traded, With 3.58 Million Open Interest
Viatris Announces Appointments of Frank D'Amelio and Michael Severino, M.D., to the Company's Board of Directors
Pfizer | 10-Q: Q1 2025 Earnings Report
Optimism Is Back for Biotech Stocks. This Time, It Could Last. -- Barrons.com